SK-JHRCC-3 is a human clear cell renal cell carcinoma (ccRCC) cell line that displays epithelial morphology and grows in adherent culture. When grown in Matrigel 3D culture, this cell line forms round colonies. The SK-JHRCC-3 cells are a useful preclinical model to study renal cancer. They form tumors when inoculated subcutaneously in immunocompromised NSG mice. These xenograft tumors are sensitive to Sunitinib (oral, small molecule, multi-targeted receptor tyrosine kinase inhibitor, approved for the treatment of renal cell carcinoma) in vivo. Histological analysis shows that SK-JHRCC-3 tumor xenografts exhibit the same clear cell feature as the primary tumor from which they were derived. Immunohistochemistry analysis shows that SK-JHRCC-3 xenograft tumors are positive for PAX8 and CAIX expression. Exome sequencing revealed that these cells have mutations in PBRM1 and SETD2 and express wildtype BAP1, KDM5C, PTEN, mTOR, and PIK3CA.
This cell line was established in 2011 from the primary tumor of a 71-year-old Caucasian male with clear cell carcinoma of the kidney and was responsive to treatment with Sunitinib.
- James J. Hsieh, MD, PhD, Laboratory Head, Memorial Hospital Research Laboratories, Human Oncology & Pathogenesis Program, Memorial Sloan Kettering
- Emily H. Cheng, MD, PhD, Laboratory Head, Memorial Hospital Research Laboratories, Human Oncology & Pathogenesis Program, Memorial Sloan Kettering
- Yiyu Dong, PhD, Research Associate, Hsieh Laboratory, Memorial Hospital Research Laboratories, Human Oncology & Pathogenesis Program, Memorial Sloan Kettering
This cell line may be licensed nonexclusively for research or commercial purposes.
- For licensing requests: Alexandra Buga, MBA, Business Development Analyst, Office of Technology Development, MSK, 646-888-1078, firstname.lastname@example.org
- For non-licensing requests from academic-research institutions: Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354, email@example.com